JP2001524941A - 可溶性放射性有毒物質の酵素変換による、癌治療のための方法および組成物 - Google Patents

可溶性放射性有毒物質の酵素変換による、癌治療のための方法および組成物

Info

Publication number
JP2001524941A
JP2001524941A JP53119198A JP53119198A JP2001524941A JP 2001524941 A JP2001524941 A JP 2001524941A JP 53119198 A JP53119198 A JP 53119198A JP 53119198 A JP53119198 A JP 53119198A JP 2001524941 A JP2001524941 A JP 2001524941A
Authority
JP
Japan
Prior art keywords
precipitate
soluble
extracellular
therapeutic agent
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP53119198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001524941A5 (enExample
Inventor
サミュエル・ローズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2001524941A publication Critical patent/JP2001524941A/ja
Publication of JP2001524941A5 publication Critical patent/JP2001524941A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP53119198A 1997-01-13 1998-01-13 可溶性放射性有毒物質の酵素変換による、癌治療のための方法および組成物 Pending JP2001524941A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/782,219 US6080383A (en) 1997-01-13 1997-01-13 Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
US08/782,219 1997-01-13
PCT/US1998/000511 WO1998030247A1 (en) 1997-01-13 1998-01-13 A method and composition for cancer treatment by enzymatic conversion of soluble radioactive toxic agents

Publications (2)

Publication Number Publication Date
JP2001524941A true JP2001524941A (ja) 2001-12-04
JP2001524941A5 JP2001524941A5 (enExample) 2005-09-08

Family

ID=25125383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53119198A Pending JP2001524941A (ja) 1997-01-13 1998-01-13 可溶性放射性有毒物質の酵素変換による、癌治療のための方法および組成物

Country Status (5)

Country Link
US (2) US6080383A (enExample)
EP (1) EP1047456A4 (enExample)
JP (1) JP2001524941A (enExample)
AU (1) AU5913198A (enExample)
WO (1) WO1998030247A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807136B2 (en) * 1997-01-13 2010-10-05 David S. Rose Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
US20030068382A1 (en) * 1999-05-18 2003-04-10 Samuel Rose Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
CA2322969A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Methods to provoke anti-cancer immune responses
US7514067B2 (en) 2000-04-25 2009-04-07 President And Fellows Of Harvard College Methods for tumor diagnosis and therapy
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US7067148B2 (en) * 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US6565537B2 (en) * 2001-04-18 2003-05-20 Dennis R. Tollini Tube securing assembly
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030190350A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US7615221B2 (en) * 2004-07-23 2009-11-10 Oncologic, Inc. Compositions and methods for treating cancer
WO2021215952A1 (ru) 2020-04-24 2021-10-28 Общество С Ограниченной Ответственностью "Индженик" Способ получения частиц бактериофагов семейства levivirus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189470A (en) * 1973-01-30 1980-02-19 Bio-Response, Inc. Method for the continuous removal of a specific antibody from the lymph fluid in animals and humans
US3964467A (en) * 1973-01-30 1976-06-22 Bio Response Inc. Methods and apparatus for augmentation of the production of anti-bodies in animals and humans and the collection thereof
CA1041445A (en) * 1973-04-09 1978-10-31 Sam Rose Method and apparatus for continuous mass in vitro suspension culture of cells
EP0109861A3 (en) * 1982-11-23 1986-05-14 Bio-Response Inc. Method for isolating cells
IN165717B (enExample) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5589328A (en) * 1994-08-04 1996-12-31 Mahant; Vijay K. Chemiluminescence assays based on indoxyl substrates, thioindoxyl substrates and other substrates

Also Published As

Publication number Publication date
US6468503B2 (en) 2002-10-22
US6080383A (en) 2000-06-27
EP1047456A1 (en) 2000-11-02
AU5913198A (en) 1998-08-03
WO1998030247A1 (en) 1998-07-16
EP1047456A4 (en) 2004-06-16
US20020022003A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
Wu et al. Metal-free bioorthogonal click chemistry in cancer theranostics
JP2001524941A (ja) 可溶性放射性有毒物質の酵素変換による、癌治療のための方法および組成物
Yang et al. Chlorin e6 and CRISPR-Cas9 dual-loading system with deep penetration for a synergistic tumoral photodynamic-immunotherapy
JPH03503898A (ja) 薬剤輸送系に関する更なる改良
US5182107A (en) Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
JP4113670B2 (ja) プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用
Singh et al. Protease responsive nanogels for transcytosis across the blood− brain barrier and intracellular delivery of radiopharmaceuticals to brain tumor cells
JP2005501011A (ja) 組織特異的内皮膜タンパク質
JP2020507329A (ja) 機能化赤血球系細胞
JPH02503088A (ja) 抗体フラグメント複合体の調製方法
JPH04503945A (ja) 血管透過性抱合体
JP2008535475A (ja) Ｑ３ｓｐａｒｃ欠失変異体及びその使用
JP2018515066A (ja) がんの診断及び処置のための組成物及び方法
EP4309677A1 (en) Pd-l1 and tlr7 double-targeting nanobody coupling drug and use thereof in anti-tumor
JP2005501052A (ja) ポリマー送達系
AU2008281901B2 (en) Oxidized avidin with high residency time in the treated tissues
JPH05503933A (ja) 化合物
JPH10503478A (ja) 細胞核に毒性放射性同位元素を伝達するための組成物及びその使用
CA2323210C (en) Enhancement of intracellular delivery and tissue targeting of drugs and genes
US6602988B2 (en) Cyclodextrin dimers with spacers having peptide structures for encapsulation of pharmaceutically active substances with potential high side-effects
US20030068382A1 (en) Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
US20180044635A1 (en) Surface-modified macrophages for cell-based delivery
EP0485749A2 (en) Chemical modification of antibodies for creating of immunoconjugates
JP2008507562A (ja) がんへのホットスポット放射線の多段階送達のための組成物
KR20200012254A (ko) 암세포 특이적 항암 단백질-형광 복합체 및 이를 포함하는 암의 진단 및 영상화용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080714

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081111